MiNK Therapeutics, Inc. , a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases.
Mink Therapeutics stock last closed at $12.81, down 4.76% from the previous day, and has increased 75.72% in one year. It has overperformed other stocks in the Biotechnology industry by 1.3 percentage points. Mink Therapeutics stock is currently +180.92% from its 52-week low of $4.56, and -83.14% from its 52-week high of $76.00.
As of Nov 4, 2025, there are 4.52M INKT shares outstanding. The market value of INKT is $57.94M. In the last 24 hours, 16,900 INKT shares were traded.
You need a brokerage account to access the NASDAQ market and buy INKT stock.
Based on our experience, eToro is the best stock brokerage. eToro gives you:
Get $10 towards your share purchase by opening an account with eToro now. This offer is only for US users.
Open eToro AccountNow that you've selected the best brokerage, you need to fill out some personal info so you can invest in INKT stock today.
Now that you've finished signing up on the best investment app, your next step is to transfer the money for your investment:
Check out the tutorial below for more details depositing funds into your brokerage account.
After you have figured out the best place to buy Mink Therapeutics stock, it's absolutely critical to analyze their stock before you invest, so you actually wrap your head around the risk as well as the opportunity.
WallStreetZen was built to help everyday investors do more in-depth fundamental analysis.
You can view all of the due diligence checks on INKT's stock page.
Analysts use many financial metrics, analyses, models, and charts to gauge INKT's fair value.
You can access more valuation research on INKT's stock here.
Out of 1 Equities analysts who give forecasts on INKT, the consensus analyst rating on INKT is a Buy
Please note that analyst ratings are not recommendations, nor are they financial advice.
You can dive deeper into what analysts are saying on the Mink Therapeutics stock forecast page.
Over the past 12 months, insiders at INKT have bought more shares than they have sold.
Jennifer Buell, Chief Executive Officer of INKT, was the latest INKT insider to buy. They bought $279,997.44 worth of INKT stock on Sep 9, 2025.
Research more about who owns INKT stock here.
No, Mink Therapeutics doesn't provide an income stream by paying out dividends.
One of the major reasons eToro is our top-rated brokerage is because of its social trading community.
Click below to find out what other traders have to say.
There are two main types of orders:
Press the Open button and your broker will place your order.
If you want additional assistance buying stocks on eToro, click the how to video below:
Now that you own some INKT stock, you'll want to keep up with your new investment.
Add INKT to a watchlist to get the latest updates about your INKT stock.
To summarize, here are the 6 steps to buy Mink Therapeutics stock:
If you need a online brokerage, eToro is our recommended venue.
Get Started with eToro TodayIf you would like to get notifications regarding your new investment in Mink Therapeutics, create a watchlist on WallStreetZen today.